article · Clinical Phytoscience
Abstract Background Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype associated with poor prognosis, metastasis, and limited targeted therapies. This study developed a folate-functionalized chitosan nanoparticle system targeting the miR-34a/NOTCH1 signaling axis and evaluated its anticancer potential using in vitro, in vivo, and bioinformatics approaches. Methods Nanoparticles were synthesized by ionic gelation and characterized for size, surface charge, polydispersity, and drug-release behavior. Tumor-targeting efficiency was enhanced through folic acid functionalization. Biological effects were assessed in MDA-MB-231 cells using viability, migration, invasion, and tumorsphere assays. Mechanistic studies included dual-luciferase reporter assays, rescue experiments, transcriptomic profiling, and TCGA-based bioinformatics analyses. Antitumor efficacy, pharmacokinetics, biodistribution, toxicity, and survival outcomes were evaluated in vivo. Results The nanoparticles exhibited nanoscale size, low polydispersity, positive zeta potential, and sustained drug release. Treatment significantly upregulated miR-34a and suppressed NOTCH1 signaling. Transcriptomic analysis revealed downregulation of epithelial–mesenchymal transition, stemness, and tumor progression pathways. Functionally, nanoparticle treatment reduced TNBC cell viability, migration, invasion, and tumorsphere formation. In vivo, the formulation inhibited tumor growth, reduced metastatic burden, prolonged survival, and showed minimal systemic toxicity relative to conventional chemotherapy. Pharmacokinetic studies demonstrated prolonged circulation and preferential tumor accumulation. Combination therapy with doxorubicin produced synergistic anticancer effects. TCGA analysis confirmed an inverse correlation between miR-34a and NOTCH1 and supported their prognostic relevance in TNBC. Conclusion Folate-functionalized chitosan nanoparticles targeting the miR-34a/NOTCH1 axis represent a promising nanotherapeutic strategy for suppressing TNBC progression and metastasis while improving therapeutic efficacy and safety.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s40816-026-00440-6
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.